The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.-Reference-Cited by-同舟云学术

The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.

Published:1993-04 Issue:4 Volume:35 Page:419-425
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Rolan PE,Parker JE,Gray SJ,Weatherley BC,Ingram J,Leavens W,Wootton R,Posner J

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1993.tb04160.x/fullpdf

Reference12 articles.

1. The painful crisis of homozygous sickle cell disease. A study of risk factors;Baum;Arch. Int. Med.,1987

2. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes;Beddell;Br. J. Pharmac.,1984

3. Sickle cell anaemia. Molecular and cellular bases of therapeutic approaches. Part 1;Dean;New Engl. J. Med.,1978a

4. Sickle cell anaemia. Molecular and cellular bases of therapeutic approaches, Part 3;Dean;New Engl. J. Med.,1978b

5. Sickle cell disease: the proportion of liganded haemolobin needed to prevent crises;Franklin;Br. J. Haematol.,1983

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. X-ray crystallography and sickle cell disease drug discovery—a tribute to Donald Abraham;Frontiers in Molecular Biosciences;2023-05-24

2. Tucaresol: A Unique Oral Candidate Drug Ideally Accessible for Treatment of Covid-19 Disease;African Journal of Pharmaceutical Sciences;2023-03-05

3. Protein aggregation-inhibition: a therapeutic route from Parkinson’s disease to sickle cell anemia;Critical Reviews in Biochemistry and Molecular Biology;2023-01-02

4. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property;Expert Opinion on Therapeutic Patents;2021-11-01

5. Target Validation—Prosecuting the Target;Reference Module in Biomedical Sciences;2021